Supplement to the FY2010 Single-Source Cooperative Agreement With the World Health Organization (WHO), 54235-54236 [2011-22214]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 169 / Wednesday, August 31, 2011 / Notices
(Commission Meeting Room), 445 12th
Street, SW., Washington, DC 20554.
found at: https://www.fcc.gov/pshs/
advisory/csric/.
FOR FURTHER INFORMATION CONTACT:
Federal Communications Commission.
Marlene H. Dortch,
Secretary.
Jeffery Goldthorp, Designated Federal
Officer of the FCC’s CSRIC, (202) 418–
1096 (voice) or jeffery.goldthorp@fcc.gov
(e-mail); or Lauren Kravetz, Deputy
Designated Federal Officer of the FCC’s
CSRIC, (202) 418–7944 (voice) or
lauren.kravetz@fcc.gov (e-mail).
The
CSRIC is a Federal Advisory Committee
that will provide recommendations to
the FCC regarding best practices and
actions the FCC can take to ensure the
security, reliability, and interoperability
of communications systems. On March
19, 2011, the FCC, pursuant to the
Federal Advisory Committee Act,
renewed the charter for the CSRIC for a
period of two years through March 18,
2013.
At this first meeting, the chairs of
each CSRIC working group will present
a plan for completion of each working
group’s tasks. A presentation will also
be made by the Alliance for
Telecommunications Industry Solutions
on recent work to improve 9–1–1
reliability. The FCC will attempt to
accommodate as many people as
possible; however, admittance will be
limited to seating availability. The
Commission will provide audio and/or
video coverage of the meeting over the
Internet from the FCC’s Web page at
https://www.fcc.gov/live. The public may
submit written comments before the
meeting to Jeffery Goldthorp, the FCC’s
Designated Federal Officer for the
CSRIC by e-mail to
jeffery.goldthorp@fcc.gov or U.S. Postal
Service Mail to Jeffery Goldthorp,
Associate Bureau Chief, Public Safety
and Homeland Security Bureau, Federal
Communications Commission, 445 12th
Street, SW., Room 7–A325, Washington,
DC 20554.
Open captioning will be provided for
this event. Other reasonable
accommodations for people with
disabilities are available upon request.
Requests for such accommodations
should be submitted via e-mail to
fcc504@fcc.gov or by calling the
Consumer & Governmental Affairs
Bureau at (202) 418–0530 (voice), (202)
418–0432 (tty). Such requests should
include a detailed description of the
accommodation needed. In addition,
please include a way the FCC can
contact you if it needs more
information. Please allow at least five
days’ advance notice; last minute
requests will be accepted, but may be
impossible to fill. Additional
information regarding the CSRIC can be
jlentini on DSK4TPTVN1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Mar<15>2010
16:51 Aug 30, 2011
Jkt 223001
[FR Doc. 2011–22201 Filed 8–30–11; 8:45 am]
BILLING CODE 6712–01–P
FEDERAL ELECTION COMMISSION
Sunshine Act Notice
Federal Election Commission.
DATE AND TIME: Wednesday, August 31,
2011, at 10 a.m.
PLACE: 999 E Street, NW., Washington,
DC (Ninth Floor).
STATUS: This hearing will be open to the
public.
ITEM TO BE DISCUSSED: Chris Dodd for
President, Inc.
Individuals who plan to attend and
require special assistance, such as sign
language interpretation or other
reasonable accommodations, should
contact Shawn Woodhead Werth,
Commission Secretary and Clerk, at
(202) 694–1040, at least 72 hours prior
to the hearing date.
PERSON TO CONTACT FOR INFORMATION:
Judith Ingram, Press Officer, Telephone:
(202) 694–1220.
AGENCY:
Shawn Woodhead Werth,
Secretary and Clerk of the Commission.
[FR Doc. 2011–22365 Filed 8–29–11; 11:15 am]
BILLING CODE 6715–01–P
FEDERAL MARITIME COMMISSION
Notice of Agreement Filed
The Commission hereby gives notice
of the filing of the following agreement
under the Shipping Act of 1984.
Interested parties may submit comments
on the agreement to the Secretary,
Federal Maritime Commission,
Washington, DC 20573, within ten days
of the date this notice appears in the
Federal Register. A copy of the
agreement is available through the
Commission’s Web site (https://
www.fmc.gov) or by contacting the
Office of Agreements at (202)–523–5793
or tradeanalysis@fmc.gov.
Agreement No.: 012070–003.
Title: CSCL/ELJSA Vessel Sharing
Agreement—Asia and Mexico, US East
Coast Service.
Parties: China Shipping Container
Lines Co., Ltd.; China Shipping
Container Lines (Hong Kong) Co., Ltd.;
Evergreen Lines Joint Service
Agreement; and United Arab Shipping
Company S.A.G.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
54235
Filing Party: Tara L. Leiter, Esq.;
Blank Rome, LLP; Watergate; 600 New
Hampshire Avenue, NW.; Washington,
DC 20037.
Synopsis: The amendment revises the
parties’ vessel contributions and space
allocations under the agreement.
Dated: August 26, 2011.
By Order of the Federal Maritime
Commission.
Karen V. Gregory,
Secretary.
[FR Doc. 2011–22322 Filed 8–30–11; 8:45 am]
BILLING CODE 6730–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[CFDA#: 93.360]
Supplement to the FY2010 SingleSource Cooperative Agreement With
the World Health Organization (WHO)
Biomedical Advanced Research
Development Authority (BARDA),
Office of the Assistant Secretary for
Preparedness and Response (ASPR),
Department of Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
In FY 2011, HHS/ASPR/
BARDA plans to supplement the
FY2010 ‘‘Single-Source Cooperative
Agreement with the World Health
Organization (WHO) to Continue
Development of Sustainable Influenza
Vaccine Production Capacity in Under
Resourced Nations’’. BARDA currently
funds the development of vaccine
manufacturing capacity in ten
developing and emerging-economy
countries worldwide via a cooperative
agreement with the World Health
Organization (WHO). The amount of
Single Source Award is $6,021,535. The
project period is September 1, 2011,
through August 31, 2012.
SUPPLEMENTARY INFORMATION: The WHO
has proven to be a key partner and
integral to the success of the program,
which has been in existence since 2006.
Continuing the partnership with the
WHO will prove critical to the long-term
viability of this program while
bolstering the influenza vaccine
manufacturing capabilities of resourcepoor nations and global pandemic
preparedness overall.
Single Source Justification: The
International Vaccine Capacity Building
Program, supported by the Department
of Health and Human Services, Office of
the Assistant Secretary for Preparedness
and Response, Biomedical Advanced
Research and Development Authority
was developed and has been operational
SUMMARY:
E:\FR\FM\31AUN1.SGM
31AUN1
jlentini on DSK4TPTVN1PROD with NOTICES
54236
Federal Register / Vol. 76, No. 169 / Wednesday, August 31, 2011 / Notices
since 2006. In light of the threat of an
influenza pandemic it was originally
designed with the goals of bolstering
both international and domestic
pandemic preparedness and response.
The fundamental approach in achieving
these goals has been through the
development of the influenza vaccine
production capabilities of under
resourced nations in the hopes that they
will ultimately be able to produce
vaccines to protect the local, regional,
and international public health. The
program is supported by a collaborative
of U.S. Government agencies,
international organizations, foreign
ministries and/or other foreign
institutions dedicated to achieving these
goals.
The WHO is the only global
organization with the experience and
scientific standing to accomplish the
program goals. It is the recognized
world health authority within the
United Nations system. Similarly, the
liaison and support functions that the
WHO plays within the international
vaccine production capacity building
program cannot be duplicated or
replicated. Through standing
consultation and dialog with its
members states on all aspects of public
health, WHO is the only partner able to
ensure synchronization of building of
production capacity in developing
countries for influenza vaccine with
other pandemic preparedness activities
and with increase of demand for
seasonal influenza immunization.
The WHO’s strong collaborative
relationships with foreign governments,
programmatic support, and familiarity
with international vaccine production
institutions have been and will be
critical to the future viability of this
program. Over the history of the
International Vaccine Production
Capacity Building program, the WHO
has provided unique and invaluable
support to the project. Similarly, the
WHO has also independently funded
other nations/institutions working to
strengthen their influenza vaccine
production capacity; also demonstrating
their commitment to the success of this
program. The WHO represents a key
stakeholder in the implementation of
the program; providing unique
functions, technical and scientific
expertise, and capabilities that no other
organization in the world has.
Additional Information: The agency
program contact is Dr. Rick Bright,
whom can be contacted at (202) 260–
8535 or Rick.Bright@hhs.gov.
(PAHPA), Pub. L. 109–417; and the
Consolidated Appropriations Act, 2010, Pub.
L. 111–117.
Statutory Authority: Section 319L of the
Public Health Service (PHS) Act, 42 U.S.C.
247d–7e as amended by Title IV of the
Pandemic and All-Hazards Preparedness Act
(1) Delete the functional statement for
the Office of Planning, Analysis and
Evaluation (RA5) and replace in its
entirety.
VerDate Mar<15>2010
16:51 Aug 30, 2011
Jkt 223001
Dated: August 25, 2011.
Nicole Lurie,
Assistant Secretary for Preparedness and
Response, U.S. Department of Health and
Human Services.
[FR Doc. 2011–22214 Filed 8–30–11; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Statement of Organization, Functions
and Delegations of Authority
This notice amends part R of the
Statement of Organization, Functions
and Delegations of Authority of the
Department of Health and Human
Services (HHS), Health Resources and
Services Administration (HRSA) (60 FR
56605, as amended November 6, 1995;
as last amended at 76 FR 45584–45585
dated July 29, 2011).
This notice reflects organizational
changes to the Health Resources and
Services Administration. Specifically,
this notice updates the Office of
Planning, Analysis and Evaluation
(RA5) functional statement. The update
to the functional statement will better
align functional responsibility with
improved management and
administrative efficiencies and
improved alignment of current liaison
functions and policy processes within
the Office of Planning, Analysis and
Evaluation (RA5).
Chapter RA5—Office of Planning,
Analysis and Evaluation
Section RA5–10, Organization
Delete in its entirety and replace with
the following:
The Office of Policy, Analysis and
Evaluation (RA5) is headed by the
Director, who reports directly to the
Administrator, Health Resources and
Services Administration. The Office of
Planning, Analysis and Evaluation
(RA5) includes the following
components:
(1) Office of the Director (RA5);
(2) Office of Policy Analysis (RA53);
and
(3) Office of Research and Evaluation
(RA56).
Section RA5–20, Functions
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Office of the Director (RA5)
(1) Provides Agency-wide leadership
for policy development, data collection
and management, major analytic
activities, research, and evaluation; (2)
develops HRSA-wide policies; (3)
participates with HRSA organizations in
developing strategic plans for their
component; (4) coordinates the
Agency’s long-term strategic planning
process; (5) conducts and/or guides
analyses, research, and program
evaluation; (6) develops annual
performance plans; (7) analyzes
budgetary data with regard to planning
guidelines; (8) develops and produces
performance reports required under the
Government Performance and
Accountability Report and OMB; (9) as
requested, develops, implements, and
coordinates policy processes for the
Agency for key major cross-cutting
policy issues; (10) facilitates policy
development by maintaining analytic
liaison between the Administrator, other
OPDIVs, Office of the Secretary staff
components, and other Departments on
critical matters involving program
policy undertaken in the Agency; (11)
provides data analyses, graphic
presentations, briefing materials, and
analyses on short notice to support the
immediate needs of the Administrator
and Senior Leadership; (12) conducts
special studies and analyses and/or
provides analytic support and
information to the Administrator and
Senior Leadership needed to support
the Agency’s goals and directions; and
(13) collaborates with the Office of
Operations in the development of
budgets, performance plans, and other
administration reporting requirements.
Office of Policy Analysis (RA53)
(1) Serves as the principal Agency
resource for policy analysis; (2) analyzes
issues arising from legislation, budget
proposals, regulatory actions, and other
program or policy actions; (3) serves as
focal point within HRSA for analysis of
healthcare payment systems and
financing issues; (4) collaborates with
HHS Agencies to examine the impact of
Medicare, Medicaid, and Children’s
Health Insurance Program (CHIP) on
HRSA grantees and safety net providers;
(5) provides Agency leadership
guidance on policy development; (6)
serves as a resource of information and
institutional knowledge for the Agency;
(7) coordinates the Agency’s
participation in Healthy People, and
other Department and Federal
initiatives; (8) coordinates the Agency’s
intergovernmental activities, including:
providing the Administrator with a
single point of contact on all activities
E:\FR\FM\31AUN1.SGM
31AUN1
]]>Agencies
[Federal Register Volume 76, Number 169 (Wednesday, August 31, 2011)]
[Notices]
[Pages 54235-54236]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-22214]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
[CFDA: 93.360]
Supplement to the FY2010 Single-Source Cooperative Agreement With
the World Health Organization (WHO)
AGENCY: Biomedical Advanced Research Development Authority (BARDA),
Office of the Assistant Secretary for Preparedness and Response (ASPR),
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In FY 2011, HHS/ASPR/BARDA plans to supplement the FY2010
``Single-Source Cooperative Agreement with the World Health
Organization (WHO) to Continue Development of Sustainable Influenza
Vaccine Production Capacity in Under Resourced Nations''. BARDA
currently funds the development of vaccine manufacturing capacity in
ten developing and emerging-economy countries worldwide via a
cooperative agreement with the World Health Organization (WHO). The
amount of Single Source Award is $6,021,535. The project period is
September 1, 2011, through August 31, 2012.
SUPPLEMENTARY INFORMATION: The WHO has proven to be a key partner and
integral to the success of the program, which has been in existence
since 2006. Continuing the partnership with the WHO will prove critical
to the long-term viability of this program while bolstering the
influenza vaccine manufacturing capabilities of resource-poor nations
and global pandemic preparedness overall.
Single Source Justification: The International Vaccine Capacity
Building Program, supported by the Department of Health and Human
Services, Office of the Assistant Secretary for Preparedness and
Response, Biomedical Advanced Research and Development Authority was
developed and has been operational
[[Page 54236]]
since 2006. In light of the threat of an influenza pandemic it was
originally designed with the goals of bolstering both international and
domestic pandemic preparedness and response. The fundamental approach
in achieving these goals has been through the development of the
influenza vaccine production capabilities of under resourced nations in
the hopes that they will ultimately be able to produce vaccines to
protect the local, regional, and international public health. The
program is supported by a collaborative of U.S. Government agencies,
international organizations, foreign ministries and/or other foreign
institutions dedicated to achieving these goals.
The WHO is the only global organization with the experience and
scientific standing to accomplish the program goals. It is the
recognized world health authority within the United Nations system.
Similarly, the liaison and support functions that the WHO plays within
the international vaccine production capacity building program cannot
be duplicated or replicated. Through standing consultation and dialog
with its members states on all aspects of public health, WHO is the
only partner able to ensure synchronization of building of production
capacity in developing countries for influenza vaccine with other
pandemic preparedness activities and with increase of demand for
seasonal influenza immunization.
The WHO's strong collaborative relationships with foreign
governments, programmatic support, and familiarity with international
vaccine production institutions have been and will be critical to the
future viability of this program. Over the history of the International
Vaccine Production Capacity Building program, the WHO has provided
unique and invaluable support to the project. Similarly, the WHO has
also independently funded other nations/institutions working to
strengthen their influenza vaccine production capacity; also
demonstrating their commitment to the success of this program. The WHO
represents a key stakeholder in the implementation of the program;
providing unique functions, technical and scientific expertise, and
capabilities that no other organization in the world has.
Additional Information: The agency program contact is Dr. Rick
Bright, whom can be contacted at (202) 260-8535 or Rick.Bright@hhs.gov.
Statutory Authority: Section 319L of the Public Health Service
(PHS) Act, 42 U.S.C. 247d-7e as amended by Title IV of the Pandemic
and All-Hazards Preparedness Act (PAHPA), Pub. L. 109-417; and the
Consolidated Appropriations Act, 2010, Pub. L. 111-117.
Dated: August 25, 2011.
Nicole Lurie,
Assistant Secretary for Preparedness and Response, U.S. Department of
Health and Human Services.
[FR Doc. 2011-22214 Filed 8-30-11; 8:45 am]
BILLING CODE 4150-37-P
